Sagimet Biosciences Inc. Series A Common Stock (SGMT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $735.18M
Last updated: Nov 17, 2026 at 11:06 AM ET
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Competitors
The companies most similar to Sagimet Biosciences Inc. Series A Common Stock are Inventiva Sa (IVA), Solid Biosciences LLC (SLDB) and Rigel Pharmaceuticals (RIGL). By market cap, Sagimet Biosciences Inc. Series A Common Stock ranks 7th of the 13 companies on this page; Structure Therapeutics Inc. American Depositary Shares (GPCR) is the largest at $1.43B.
Peer Comparison
SGMT's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc. Series A Common Stock (SGMT) | $735.18M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Inventiva Sa (IVA) | $879.90M | N/A | 133.4x | 0.0% | -327.7% | -76.7% | 0.00% |
| Solid Biosciences LLC (SLDB) | $763.42M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Rigel Pharmaceuticals Inc (RIGL) | $837.18M | 14.2x | 2.8x | 106.6% | 16.7% | 16.5% | 0.00% |
| Sana Biotechnology Inc (SANA) | $605.26M | N/A | N/A | 0.0% | -46.8% | 0.0% | 0.00% |
| Ginkgo Bioworks Holdings (DNA) | $622.97M | N/A | 6.1x | -192.0% | N/A | -5.7% | 0.00% |
| Surrozen Inc (SRZN) | $602.54M | N/A | 36.1x | 0.0% | N/A | 408.6% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Syndax Pharmaceuticals Inc (SNDX) | $850.77M | N/A | 2.8x | -72.3% | -65.0% | 81.6% | 0.00% |
| Prime Medicine, Inc. Common Stock (PRME) | $949.85M | N/A | 105.5x | 0.0% | N/A | 243.9% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $729.72M | 14.2x | 6.1x | 0.0% | -46.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Sagimet Biosciences Inc. Series A Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Inventiva Sa (IVA) | Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic... | |
| Solid Biosciences LLC (SLDB) | Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. | SLDB competitors |
| Rigel Pharmaceuticals Inc (RIGL) | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. | RIGL competitors |
| Sana Biotechnology Inc (SANA) | Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington. | SANA competitors |
| Ginkgo Bioworks Holdings (DNA) | Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms... | DNA competitors |
| Surrozen Inc (SRZN) | Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform... | SRZN competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Syndax Pharmaceuticals Inc (SNDX) | Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. | SNDX competitors |
| Prime Medicine, Inc. Common Stock (PRME) | Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology... | PRME competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
Frequently Asked Questions About SGMT
Who are Sagimet Biosciences Inc. Series A Common Stock's main competitors?
The companies most similar to Sagimet Biosciences Inc. Series A Common Stock include Inventiva Sa (IVA), Solid Biosciences LLC (SLDB), Rigel Pharmaceuticals (RIGL), Sana Biotechnology (SANA) and Ginkgo Bioworks Holdings (DNA), listed from the closest match.
Who is Sagimet Biosciences Inc. Series A Common Stock's biggest competitor?
Structure Therapeutics Inc. American Depositary Shares (GPCR) is the largest of the similar companies at $1.43B; Inventiva Sa (IVA) is the closest match by business profile, size, sector and industry.
How does SGMT stock compare with its competitors?
SGMT's net margin is 0.0% against a peer median of 0.0%.
Which of Sagimet Biosciences Inc. Series A Common Stock's competitors pays a higher dividend?
Sagimet Biosciences Inc. Series A Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Sagimet Biosciences Inc. Series A Common Stock bigger than its competitors?
No. Sagimet Biosciences Inc. Series A Common Stock is 7th by market cap among the 13 companies on this page; the largest is Structure Therapeutics Inc. American Depositary Shares (GPCR) at $1.43B.
SGMT pages: Overview, Earnings, Forecast, Financials, Competitors